This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Angion Biomedica Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Angion Biomedica.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	24.0%
Tasa de crecimiento de los ingresos	-122.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 May 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Apr 27

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Jan 05

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Sep 11

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

Oct 05

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Aug 18

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ANGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
3/31/2023	1	-29	-31	-31	N/A
12/31/2022	2	-39	-38	-38	N/A
9/30/2022	28	-17	-48	-48	N/A
6/30/2022	30	-24	-55	-55	N/A
3/31/2022	30	-32	-56	-56	N/A
12/31/2021	28	-55	-53	-53	N/A
9/30/2021	3	-98	-18	-18	N/A
6/30/2021	2	-100	-25	-24	N/A
3/31/2021	2	-104	-27	-27	N/A
12/31/2020	3	-80	-23	-23	N/A
9/30/2020	3	-67	-48	-48	N/A
12/31/2019	1	-41	-25	-25	N/A
12/31/2018	4	-25	-8	-8	N/A
6/30/2014	6	0	N/A	1	N/A
3/31/2014	6	0	N/A	2	N/A
12/31/2013	7	1	N/A	2	N/A
12/31/2012	7	0	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de ANGN es superior a la tasa de ahorro (2.1%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de ANGN crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de ANGN crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ANGN no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ANGN no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ANGN se prevé que sea elevada dentro de 3 años.

This company is no longer active

Angion Biomedica Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$1.50

Price target increased to US$14.75

Price target decreased to US$15.00

Recent updates

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)

Insufficient new directors

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Full year 2022 earnings released: US$1.29 loss per share (vs US$1.93 loss in FY 2021)

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Angion Biomedica Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$1.50

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.57 loss in 2Q 2021)

Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

Price target increased to US$14.75

Angion Biomedica Corp. Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease

President recently bought US$101k worth of stock

First quarter 2022 earnings released: US$0.47 loss per share (vs US$1.57 loss in 1Q 2021)

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Price target decreased to US$15.00

Full year 2021 earnings released: US$1.93 loss per share (vs US$5.43 loss in FY 2020)

We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

Angion Biomedica: Selling At Cash Value

Interim Chief Financial Officer notifies of intention to sell stock

Angion Biomedica Corp. Provides ANG-3070 Program Update

President recently bought US$730k worth of stock

President recently bought US$106k worth of stock

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Angion Biomedica Corp Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

Angion Biomedica Corp. Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from Russell Microcap Value Index

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion Biomedica Corp. announced that it has received $25 million in funding from Vifor (International) AG

Angion Biomedica Corp. has completed an IPO in the amount of $80 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento